Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives $199.53 Average PT from Analysts

Shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) have been given an average recommendation of “Moderate Buy” by the sixteen analysts that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $199.5333.

A number of analysts have commented on the stock. HC Wainwright upped their target price on shares of Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a report on Tuesday, March 24th. TD Cowen reissued a “buy” rating on shares of Palvella Therapeutics in a research report on Monday, February 2nd. BTIG Research upped their price objective on Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Stephens reaffirmed an “overweight” rating and issued a $220.00 target price on shares of Palvella Therapeutics in a report on Thursday, May 21st. Finally, Truist Financial set a $210.00 target price on Palvella Therapeutics in a research report on Tuesday, February 24th.

Insider Buying and Selling

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $117.99, for a total value of $507,592.98. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 20.50% of the stock is currently owned by insiders.

Institutional Trading of Palvella Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. KBC Group NV purchased a new stake in Palvella Therapeutics in the first quarter worth about $28,000. Group One Trading LLC increased its position in Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after buying an additional 200 shares in the last quarter. Archer Investment Corp purchased a new stake in Palvella Therapeutics in the third quarter worth about $28,000. Russell Investments Group Ltd. purchased a new stake in Palvella Therapeutics in the third quarter worth about $36,000. Finally, China Universal Asset Management Co. Ltd. purchased a new stake in Palvella Therapeutics in the fourth quarter worth about $167,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Stock Performance

Shares of NASDAQ:PVLA opened at $118.46 on Friday. The stock’s 50-day simple moving average is $121.17 and its two-hundred day simple moving average is $106.84. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of -28.41 and a beta of -0.13. Palvella Therapeutics has a 52-week low of $20.20 and a 52-week high of $151.18.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.20) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.30). As a group, equities analysts forecast that Palvella Therapeutics will post -5.26 earnings per share for the current fiscal year.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.